MAS1L and metabolic syndrome: Interestingly, the treatment of MetS rats with candesartan induced a significant increase in the fluorescence intensity of components of the anti-oxidative/anti-inflammatory RAS such as ACE2 (Figure 3E) and MasR (Figure 3F) in EVMetS+CAND.